NCT06776055View on ClinicalTrials.gov

Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women

Active, not recruitingOBSERVATIONAL
Enrollment

5,372

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Cervical CancerVulvar CancerVaginal CancerCIN - Cervical Intraepithelial NeoplasiaHuman Papillomavirus Infection
Interventions
BIOLOGICAL

HPV-16/18 vaccine

Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)

BIOLOGICAL

Placebo

Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.

Trial Locations (9)

Unknown

Lingchuan Center for Disease Control and Prevention, Lingchuan

Quanzhou Center for Disease Control and Prevention, Quanzhou

Xing'an Center for Disease Control and Prevention, Xing’an

Daming Center for Disease Control and Prevention, Daming

Dingxing Center for Disease Control and Prevention, Dingxing

Zhengding Center for Disease Control and Prevention, Zhengding

Puyang Center for Disease Control and Prevention, Puyang

Wenxian Center for Disease Control and Prevention, Wenquan

Xiangfen County People's Hospital, Xincheng

All Listed Sponsors
collaborator

Yuxi Zerun Biotechnology Co., Ltd.

UNKNOWN

lead

Shanghai Zerun Biotechnology Co.,Ltd

INDUSTRY